New England Journal Of Medicine Publishes Results From The Landmark ATHENA Trial With Multaq® (Dronedarone) In Atrial Fibrillation

Paris, France – 11 February, 2009 – Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) announced today that the ATHENA trial was published in the New England Journal of Medicine. The trial showed that Multaq® (dronedarone), in addition to standard therapy, significantly reduced the risk of first cardiovascular hospitalisation or death by 24 percent (31.9% vs. 39.4%, p<0.001)>

fore more details http://www.sanofi-aventis.com/